Flinders Study Links Adenovirus Protein to Clots
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Flinders University researchers, together with Greifswald University, identified molecular mimicry between an adenovirus vector protein (pVII) and platelet factor 4 (PF4) as the trigger for VITT.
- New England Journal of Medicine published the study, detailing mass‑spectrometry sequencing that revealed the mimicry.
- Dr. Jing Jing Wang said that modifying or removing the specific adenovirus protein can prevent the rare clotting reaction while preserving vaccine efficacy.
- Professor Tom Gordon noted that the discovery builds on earlier work decoding the PF4 autoantibody structure (2022) and a genetic risk factor (IGLV3.21*02).
- Professor Ted Warkentin previously reported that natural adenovirus infections can cause the same PF4 autoantibody, indicating the adenovirus itself—not just vaccines—can trigger VITT.
- Vaccine developers can now redesign adenovirus‑based COVID vaccines to eliminate the pVII protein, aiming for safer vaccines worldwide.
Why it matters: Vaccine manufacturers gain a concrete molecular target to eliminate, allowing them to modify adenovirus vector proteins and eradicate the VITT risk while preserving efficacy, which benefits public health systems and recipients, especially in regions reliant on adenovirus‑based COVID shots. The rare clotting side‑effect is thus rendered preventable.
Ask SkimNews
